bexarotene has been researched along with Lymphoma, Large B-Cell, Diffuse in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, PL; Malachowski, SJ; Seminario-Vidal, L; Sun, J | 1 |
| Keun, YK; Sangueza, O; Woodruff, R | 1 |
| Ardigò, M; Berardesca, E; Cota, C; Marulli, GC; Mastroianni, A | 1 |
| Commes, T; Defacque, H; Marti, J; Piquemal, D; Rochette-Egly, C; Sévilla, C | 1 |
1 review(s) available for bexarotene and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Diagnosis and Management of Cutaneous B-Cell Lymphomas.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Borrelia burgdorferi; Cyclophosphamide; Cytoreduction Surgical Procedures; Dermatologic Surgical Procedures; Disease Management; Doxorubicin; Humans; Injections, Intralesional; Lyme Disease; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Mechlorethamine; Polyethylene Glycols; Prednisone; Rituximab; Skin Neoplasms; Vincristine | 2019 |
3 other study(ies) available for bexarotene and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Response of CD30+ large cell lymphoma of skin to bexarotene.
Topics: Aged; Aged, 80 and over; Bexarotene; Female; Humans; Ki-1 Antigen; Lymphoma, Large B-Cell, Diffuse; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes | 2002 |
Bexarotene and interferon-alpha combination therapy in a patient affected by relapsing anaplastic large cell lymphoma with cutaneous involvement.
Topics: Aged; Bexarotene; Disease-Free Survival; Drug Therapy, Combination; Humans; Interferon-alpha; Lymph Nodes; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Remission Induction; Salvage Therapy; Skin Neoplasms; Tetrahydronaphthalenes | 2007 |
Potentiation of VD-induced monocytic leukemia cell differentiation by retinoids involves both RAR and RXR signaling pathways.
Topics: Alitretinoin; Animals; Benzoates; Bexarotene; Cell Differentiation; Chromans; COS Cells; HL-60 Cells; Humans; Leukemia, Monocytic, Acute; Lymphoma, Large B-Cell, Diffuse; Molecular Structure; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoid X Receptors; Retinoids; Signal Transduction; Tetrahydronaphthalenes; Transcription Factors; Transfection; Tretinoin; Tumor Cells, Cultured; Vitamin D | 1997 |